BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

British Journal of Haematology

Volumn 142, Issue 4, 2008, Pages 571-582

  José Enériz, Edurne San ^a   Román Gómez, José ^b   Cordeu, Lucia ^a   Ballestar, Esteban ^c   Gárate, Leire ^a   Andreu, Enrique J ^a   Isidro, Isabel ^d   Guruceaga, Elizabeth ^e   Jiménez Velasco, Antonio ^f   Heiniger, Anabel ^f   Torres, Antonio ^b   Calasanz, Maria José ^e   Esteller, Manel ^c   Gutiérrez, Norma C ^d   Rubio, Angel ^e   Pérez Roger, Ignacio ^g   Agirre, Xabier ^a   Prósper, Felipe ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

CD34+; Chronic myeloid leukaemia; HSPA8; Signal transduction

Indexed keywords

15 DEOXYSPERGUALIN; CHAPERONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; IMATINIB; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BCR ABL1; PROTEIN HSPA8; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ANTIGENS, CD34; CELL LINE, TUMOR; CELL SURVIVAL; CYCLINS; GENE EXPRESSION PROFILING; HSC70 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROARRAY ANALYSIS; SIGNAL TRANSDUCTION;

EID: 47649122209     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07221.x     Document Type: Article

References (68)

1. Agirre, X., Roman-Gomez, J., Jimenez-Velasco, A., Garate, L., Montiel-Duarte, C., Navarro, G., Vazquez, I., Zalacain, M., Calasanz, M.J., Heiniger, A., Torres, A., Minna, J.D. Prosper, F. (2006) ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukaemia. Oncogene, 25, 1862 1870.
2. Andreu, E.J., Lledo, E., Poch, E., Ivorra, C., Albero, M.P., Martinez-Climent, J.A., Montiel-Duarte, C., Rifon, J., Perez-Calvo, J., Arbona, C., Prosper, F. Perez-Roger, I. (2005) BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Research, 65, 3264 3272.
3. Atkins, D., Lichtenfels, R. Seliger, B. (2005) Heat shock proteins in renal cell carcinomas. Contributions to Nephrology, 148, 35 56.
4. Ballestar, E., Paz, M.F., Valle, L., Wei, S., Fraga, M.F., Espada, J., Cigudosa, J.C., Huang, T.H. Esteller, M. (2003) Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. European Molecular Biology Organization, 22, 6335 6345.
5. Becker, B., Multhoff, G., Farkas, B., Wild, P.J., Landthaler, M., Stolz, W. Vogt, T. (2004) Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Experimental Dermatology, 13, 27 32.
6. Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., Arber, D.A., Slovak, M.L. Forman, S.J. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101, 4701 4707.
7. Chant, I.D., Rose, P.E. Morris, A.G. (1995) Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. British Journal of Haematology, 90, 163 168.
8. Daley, G.Q. Baltimore, D. (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proceedings of the National Academy of Sciences. United States of America, 85, 9312 9316.
9. Daley, G.Q., Van Etten, R.A. Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247, 824 830.
10. Deininger, M.W., Vieira, S., Mendiola, R., Schultheis, B., Goldman, J.M. Melo, J.V. (2000) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Research, 60, 2049 2055.
11. Dewar, A.L., Zannettino, A.C., Hughes, T.P. Lyons, A.B. (2005) Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle, 4, 851 853.
12. Diehl, J.A., Yang, W., Rimerman, R.A., Xiao, H. Emili, A. (2003) Hsc70 regulates accumulation of cyclin D1 and cyclin D1-dependent protein kinase. Molecular and Cellular Biology, 23, 1764 1774.
13. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2, 561 566.
14. Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, F., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L. Larson, R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine, 355, 2408 2417.
15. Drysdale, M.J., Brough, P.A., Massey, A., Jensen, M.R. Schoepfer, J. (2006) Targeting Hsp90 for the treatment of cancer. Current Opinion in Drug Discovery and Development, 9, 483 495.
16. Elrick, L.J., Jorgensen, H.G., Mountford, J.C. Holyoake, T.L. (2005) Punish the parent not the progeny. Blood, 105, 1862 1866.
17. Goldman, J. Gordon, M. (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leukemia and Lymphoma, 47, 1 7.
18. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L. Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, 319 325.
19. Greiner, J., Ringhoffer, M., Taniguchi, M., Hauser, T., Schmitt, A., Dohner, H. Schmitt, M. (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. International Journal of Cancer, 106, 224 231.
20. Grillo, M., Bott, M.J., Khandke, N., McGinnis, J.P., Miranda, M., Meyyappan, M., Rosfjord, E.C. Rabindran, S.K. (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Research and Treatments, 95, 185 194.
21. de Groot, R.P., Raaijmakers, J.A., Lammers, J.W. Koenderman, L. (2000) STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Molecular Cell Biology Research Communications, 3, 299 305.
22. Guo, F., Rocha, K., Bali, P., Pranpat, M., Fiskus, W., Boyapalle, S., Kumaraswamy, S., Balasis, M., Greedy, B., Armitage, E.S., Lawrence, N. Bhalla, K. (2005) Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Research, 65, 10536 10544.
23. Gutierrez, N.C., Lopez-Perez, R., Hernandez, J.M., Isidro, I., Gonzalez, B., Delgado, M., Ferminan, E., Garcia, J.L., Vazquez, L., Gonzalez, M. San Miguel, J.F. (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia, 19, 402 409.
24. Hakansson, P., Segal, D., Lassen, C., Gullberg, U., Morse, H.C., 3rd., Fioretos, T. Meltzer, P.S. (2004) Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays. Experimental Hematology, 32, 476 482.
25. Hoos, A. Levey, D.L. (2003) Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Review of Vaccines, 2, 369 379.
26. Horita, M., Andreu, E.J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F. Fernandez-Luna, J.L. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. Journal of Experimental Medicine, 191, 977 984.
27. Hu, Y., Swerdlow, S., Duffy, T.M., Weinmann, R., Lee, F.Y. Li, S. (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 103, 16870 16875.
28. Ishida, N., Hayashi, K., Hoshijima, M., Ogawa, T., Koga, S., Miyatake, Y., Kumegawa, M., Kimura, T. Takeya, T. (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. Journal of Biological Chemistry, 277, 41147 41156.
29. Jameel, A., Skilton, R.A., Campbell, T.A., Chander, S.K., Coombes, R.C. Luqmani, Y.A. (1992) Clinical and biological significance of HSP89 alpha in human breast cancer. International Journal of Cancer, 50, 409 415.
30. Janssen, J.J., Klaver, S.M., Waisfisz, Q., Pasterkamp, G., de Kleijn, D.P., Schuurhuis, G.J. Ossenkoppele, G.J. (2005) Identification of genes potentially involved in disease transformation of CML. Leukemia, 19, 998 1004.
31. Jena, N., Deng, M., Sicinska, E., Sicinski, P. Daley, G.Q. (2002) Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Research, 62, 535 541.
32. Jorgensen, H.G., Copland, M., Allan, E.K., Jiang, X., Eaves, A., Eaves, C. Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12, 626 633.
33. Joung, Y.H., Lim, E.J., Lee, M.Y., Park, J.H., Ye, S.K., Park, E.U., Kim, S.Y., Zhang, Z., Lee, K.J., Park, D.K., Park, T., Moon, W.K. Yang, Y.M. (2005) Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells. Experimental and Molecular Medicine, 37, 353 364.
34. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J.D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L. Ottmann, O.G. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. The New England Journal of Medicine, 354, 2542 2551.
35. Kristt, D., Turner, I., Koren, R., Ramadan, E. Gal, R. (2000) Overexpression of cyclin D1 mRNA in colorectal carcinomas and relationship to clinicopathological features: an in situ hybridization analysis. Pathology and Oncology Research, 6, 65 70.
36. Kronenwett, R., Butterweck, U., Steidl, U., Kliszewski, S., Neumann, F., Bork, S., Blanco, E.D., Roes, N., Graf, T., Brors, B., Eils, R., Maercker, C., Kobbe, G., Gattermann, N. Haas, R. (2005) Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene, 24, 5313 5324.
37. Landis, M.W., Pawlyk, B.S., Li, T., Sicinski, P. Hinds, P.W. (2006) Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell, 9, 13 22.
38. Leslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y.B., Paz, K., Darnell, J.E., Albanese, C., Sakamaki, T., Pestell, R. Bromberg, J. (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Research, 66, 2544 2552.
39. Li, S., Ilaria, R.L., Jr., Million, R.P., Daley, G.Q. Van Etten, R.A. (1999) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Journal of Experimental Medicine, 189, 1399 1412.
40. Li, Z., Qiao, Y., Liu, B., Laska, E.J., Chakravarthi, P., Kulko, J.M., Bona, R.D., Fang, M., Hegde, U., Moyo, V., Tannenbaum, S.H., Menoret, A., Gaffney, J., Glynn, L., Runowicz, C.D. Srivastava, P.K. (2005) Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clinical Cancer Research, 11, 4460 4468.
41. Liu, J.H., Yen, C.C., Lin, Y.C., Gau, J.P., Yang, M.H., Chao, T.C., Hsiao, L.T., Wang, W.S., Tsai, Y.C. Chen, P.M. (2004) Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. Leukemia and Lymphoma, 45, 2419 2425.
42. Martinez-Cruz, L.A., Rubio, A., Martinez-Chantar, M.L., Labarga, A., Barrio, I., Podhorski, A., Segura, V., Sevilla Campo, J.L., Avila, M.A. Mato, J.M. (2003) garban: genomic analysis and rapid biological annotation of cDNA microarray and proteomic data. Bioinformatics, 19, 2158 2160.
43. Mhawech, P., Greloz, V., Oppikofer, C., Szalay-Quinodoz, I. Herrmann, F. (2004) Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer, 100, 2367 2375.
44. Moreno-Bueno, G., Rodriguez-Perales, S., Sanchez-Estevez, C., Marcos, R., Hardisson, D., Cigudosa, J.C. Palacios, J. (2004) Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. International Journal of Cancer, 110, 194 200.
45. Nadeau, K., Nadler, S.G., Saulnier, M., Tepper, M.A. Walsh, C.T. (1994) Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry, 33, 2561 2567.
46. Nadler, S.G., Tepper, M.A., Schacter, B. Mazzucco, C.E. (1992) Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science, 258, 484 486.
47. Nadler, S.G., Eversole, A.C., Tepper, M.A. Cleaveland, J.S. (1995) Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Therapeutic Drug Monitoring, 17, 700 703.
48. Nadler, S.G., Dischino, D.D., Malacko, A.R., Cleaveland, J.S., Fujihara, S.M. Marquardt, H. (1998) Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochemical and Biophysical Research Communications, 253, 176 180.
49. Nakashima, M., Meirmanov, S., Naruke, Y., Kondo, H., Saenko, V., Rogounovitch, T., Shimizu-Yoshida, Y., Takamura, N., Namba, H., Ito, M., Abrosimov, A., Lushnikov, E., Roumiantsev, P., Tsyb, A., Yamashita, S. Sekine, I. (2004) Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. Journal of Pathology, 202, 446 455.
50. Nowicki, M.O., Pawlowski, P., Fischer, T., Hess, G., Pawlowski, T. Skorski, T. (2003) Chronic myelogenous leukemia molecular signature. Oncogene, 22, 3952 3963.
51. Ogata, M., Naito, Z., Tanaka, S., Moriyama, Y. Asano, G. (2000) Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch, 67, 177 185.
52. Okuda, K., Weisberg, E., Gilliland, D.G. Griffin, J.D. (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood, 97, 2440 2448.
53. Page, R.D. (1996) TreeView: an application to display phylogenetic trees on personal computers. Computer Applications in the Biosciences, 12, 357 358.
54. Pocaly, M., Lagarde, V., Etienne, G., Ribeil, J.A., Claverol, S., Bonneu, M., Moreau-Gaudry, F., Guyonnet-Duperat, V., Hermine, O., Melo, J.V., Dupouy, M., Turcq, B., Mahon, F.X. Pasquet, J.M. (2007) Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia, 21, 93 101.
55. Quintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O'Brien, S., Giles, F., Talpaz, M. Cortes, J. (2006) Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 109, 497 499.
56. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J.A., Navarro, G., Barrios, M., Andreu, E.J., Prosper, F., Heiniger, A. Torres, A. (2004) Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. British Journal of Cancer, 91, 707 713.
57. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Cervantes, F., Sanchez, J., Garate, L., Barrios, M., Castillejo, J.A., Navarro, G., Colomer, D., Prosper, F., Heiniger, A. Torres, A. (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene, 24, 7213 7223.
58. Roman-Gomez, J., Jimenez-Velasco, A., Agirre, X., Castillejo, J.A., Navarro, G., Garate, L., Jose-Eneriz, E.S., Cordeu, L., Barrios, M., Prosper, F., Heiniger, A. Torres, A. (2006) Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia, 20, 1445 1448.
59. San Jose-Eneriz, E., Agirre, X., Roman-Gomez, J., Cordeu, L., Garate, L., Jimenez-Velasco, A., Vazquez, I., Calasanz, M.J., Heiniger, A., Torres, A. Prosper, F. (2006) Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. British Journal of Haematology, 134, 137 144.
60. Savage, D.G. Antman, K.H. (2002) Imatinib mesylate - a new oral targeted therapy. The New England Journal of Medicine, 346, 683 693.
61. Stendahl, M., Kronblad, A., Ryden, L., Emdin, S., Bengtsson, N.O. Landberg, G. (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. British Journal of Cancer, 90, 1942 1948.
62. Tan, P.G., Xing, Z. Li, Z.Q. (2004) [Expression of cyclin D1 in brain gliomas and its significance]. Chinese Journal of Cancer, 23, 63 65.
63. Tepper, M.A., Nadler, S.G., Esselstyn, J.M. Sterbenz, K.G. (1995) Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. Journal of Immunology, 155, 2427 2436.
64. Tipping, A.J., Deininger, M.W., Goldman, J.M. Melo, J.V. (2003) Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Experimental Hematology, 31, 1073 1080.
65. Tusher, V.G., Tibshirani, R. Chu, G. (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America, 98, 5116 5121.
66. Weisberg, E. Griffin, J.D. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95, 3498 3505.
67. Wu, M.Y., Zhuang, C.X., Yang, H.X. Liang, Y.R. (2004) Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study. World J Gastroenterol, 10, 476 480.
68. Yu, Q., Sicinska, E., Geng, Y., Ahnstrom, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L.N., Stal, O. Sicinski, P. (2006) Requirement for CDK4 kinase function in breast cancer. Cancer Cell, 9, 23 32.